Treatment of atrial fibrillation in horses by intravenous administration of quinidine.

The study explores the use of quinidine gluconate, administered intravenously, in treating horses afflicted with atrial fibrillation (AF), finding it to be a viable treatment method in the majority of cases.

Objective of the Research

The primary aim of this study was to investigate the effectiveness of intravenous administration of quinidine gluconate in converting AF (atrial fibrillation) to sinus rhythm (normal heartbeat) in horses. The researchers hypothesized that intravenous administration of this medicine could act as a suitable alternative for treating AF in some horses.

Methodology

• The research involved a sample of 12 horses that had been diagnosed with AF via ECG (electrocardiogram).
• The horses received up to 11 mg/kg of quinidine gluconate in bolus injections ranging from 1.0 to 1.5 mg/kg every 10 to 15 minutes.
• The total dosage of quinidine administered intravenously ranged from 1.8 to 5.8 g and was dependent on the weight of the horse.

Results and Findings

• The treatment was successful in converting AF to sinus rhythm in 9 out of the 12 horses, suggesting a success rate of 75%.
• Side effects observed during the treatment included increased ventricular rate, apprehension, and mild depression.
• No critical signs of toxicosis were observed during the study.
• One particular horse was successfully treated with intravenous quinidine gluconate on three separate occasions, indicating potential repeatability of the treatment.

Conclusions

The study concludes that the intravenous administration of quinidine gluconate can be a safe and effective method for treating atrial fibrillation in horses. While some side effects were seen, no severe signs of toxicosis were observed. The research provides encouraging evidence for the use of this treatment method, although further research may be required to consolidate these findings.